Enoxaparin treatment for poor fetal growth and low amniotic fluid
Treatments studied
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This trial tests whether a blood-thinning medication, enoxaparin, can improve outcomes for babies diagnosed with intrauterine growth restriction (poor growth) and too little amniotic fluid. It aims to see if treatment leads to better health for the baby at birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old
- You are pregnant with one baby (not twins or more)
- You are at least 28 weeks pregnant
- Your baby has been diagnosed with poor growth (intrauterine growth restriction) and you have too little amniotic fluid (oligohydramnios)
- You do not have major medical conditions like uncontrolled diabetes, chronic high blood pressure, or kidney disease
- You are not already taking blood thinners or have a blood clotting disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses an MRI scan to look at placental health in pregnancies where the baby (or one twin) is not growing as expected. The goal is to better understand placental problems and how they may affect baby growth.
This trial looks at how to diagnose and manage pregnancies and babies affected by slow growth before birth, birth defects, or chromosome-related conditions. It may help by improving how doctors confirm problems and plan care for mothers and newborns.
This study looks at therapies meant to support brain development in babies whose growth is slower than expected before birth. It enrolls pregnancies in a specific time window and uses ultrasound/Doppler testing to make sure the baby is not likely needing delivery immediately.
This study tests whether a blood-thinner medicine (LMWH) can improve outcomes for people carrying a singleton baby with early signs of slow growth. It compares LMWH against standard care to see if treatment helps the baby and pregnancy stay safer.
This trial tests whether a blood-thinning medication (enoxaparin) can help prevent complications like preterm birth or preeclampsia from happening again. It is for people who had a past pregnancy problem tied to placenta blood flow issues.
This study looks at how early, slow fetal growth is managed during pregnancy. It compares an “angiogenic factors” approach with an ultrasound (blood-flow) approach to help guide care and improve outcomes.
Hear when a new Intrauterine Growth Restriction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.